Temporal alterations in pericytes at the acute phase of ischemia/reperfusion in the mouse brain  

作　　者：Shuang Zhang Xue-Jing Liao Jia Wang Yi Shen Han-Fen Shi Yan Zou Chong-Yang Ma Xue-Qian Wang Qing-Guo Wang Xu Wang Ming-Yang Xu Fa-Feng Cheng Wan-Zhu Bai 

机构地区：[1]Beijing Key Laboratory,School of Basic Medical Sciences,Beijing University of Chinese Medicine,Beijing,China [2]Institute of Acupuncture and Moxibustion,China Academy of Chinese Medical Sciences,Beijing,China [3]Shineway Pharmaceutical Group Ltd.,Shijiazhuang,Hebei Province,China [4]School of Traditional Chinese Medicine,Capital Medical University,Beijing,China

出　　处：《Neural Regeneration Research》2022年第10期2247-2252,共6页中国神经再生研究（英文版）

基　　金：financially supported by the China Academy of Chinese Medical Sciences Innovation Fund,No.CI2021A03407(to WZB);the National Natural Science Foundation of China,No.81973789(to FFC).

摘　　要：Pericytes,as the mural cells surrounding the microvasculature,play a critical role in the regulation of microcirculation;however,how these cells respond to ischemic stroke remains unclear.To determine the temporal alterations in pericytes after ischemia/reperfusion,we used the 1-hour middle cerebral artery occlusion model,which was examined at 2,12,and 24 hours after reperfusion.Our results showed that in the reperfused regions,the cerebral blood flow decreased and the infarct volume increased with time.Furthermore,the pericytes in the infarct regions contracted and acted on the vascular endothelial cells within 24 hours after reperfusion.These effects may result in incomplete microcirculation reperfusion and a gradual worsening trend with time in the acute phase.These findings provide strong evidence for explaining the“no-reflow”phenomenon that occurs after recanalization in clinical practice.

关 键 词：acute ischemic stroke alpha-smooth muscle cerebral blood flow MICROCIRCULATION no-reflow phenomenon PERICYTES platelet endothelial cell adhesion molecule-1 platelet-derived growth factor receptor beta vascular endothelial cells 

分 类 号：R-332[医药卫生] R741